Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice [NA]

View source ↗

Summary

A completed clinical trial evaluating neoadjuvant dual HER2 blockade with pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma) in early HER2-positive breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Herzuma (CT-P6) / trastuzumab biosimilar (trastuzumab)
• Perjeta (pertuzumab) (pertuzumab)

Snippet

Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Conditions: Breast Cancer | NA | Status: COMPLETED